Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN45741714

Enrollment

320

Registered

2006-02-06

Start date

2006-01-31

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypogonadal men with decreased insulin sensitivity Nutritional, Metabolic, Endocrine Testicular hypofunction

Interventions

Once daily testosterone replacement gel 2% versus placebo gel

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Hypogonadal males 2. Decreased insulin sensitivity

Exclusion criteria

Exclusion criteria: 1. Use of testosterone replacement therapy in the last six months 2. History of or current prostate carcinoma

Design outcomes

Primary

Measure	Time frame
Change in insulin sensitivity	—

Secondary

Measure	Time frame
1. Change in abdominal obesity, lipid profile and glycaemic control 2. Change in symptoms of hypogonadism 3. The safety and tolerability of testosterone replacement gel compared to placebo gel	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026